FDA accepts Alzheimer drug for traditional approval path - Breaking The News

FDA accepts Alzheimer drug for traditional approval path

6 March

1 min read

EPA-EFE/CJ GUNTHER

Eisai Co. Ltd. and Biogen Inc. announced on Monday that the United States Food and Drug Administration (FDA) accepted their application to convert the accelerated to a traditional approval of Leqembi (lecanemab) treatment for Alzheimer's disease.

In January, the drug was authorized under an expedited procedure which is used as a path to greenlight drugs for serious conditions where there is an unmet medical need.

Leqembi is used in patients with mild cognitive impairment or mild dementia stage of the disease, and the latest application is based upon the completed Phase 3 clinical trial.

biogen fda eisai

Related Stocks

Biogen Idec

EISAI

Trump: FDA should speed up approvals of US-made drugs

8 hours ago

United States President Donald Trump signed on Monday the executive order to instruct the Food and Drug Administration (FDA) to speed up the process of approving domestically made medicines.The president also directed the agency to raise its fees for foreign drug-manufacturing plants in the US and make more frequent and stricter inspections. He also urged the department to be more stern regarding the pharmaceutical companies' reporting on their...

Biogen logs Q1 revenue of $2.4 billion, up 6%

1 May

Biogen Inc. revealed on Thursday in a press release that its total revenue in the first trimester of its fiscal 2025 amounted to $2.4 billion, up 6% compared to the same timeframe in 2024.Meanwhile, in the reported period, GAAP diluted earnings per share slumped year over year to reach $1.64. In addition, net income attributable to Biogen Inc. in the three months ending March 31 came in at $240.5 million."Biogen delivered strong first-quarter results, supporting...

US FDA vaccine director resigns

29 March

Director of the United States Center for Biologics Evaluation and Research, Dr. Peter Marks (pictured), the head of the US Food and Drug Administration (FDA) responsible for verifying the safety and efficacy of vaccines, has resigned effective April 5, the Wall Street Journal reported. "It has become clear that truth and transparency are not desired by the [US Health and Human Services (HHS)] Secretary [Robert F. Kennedy Jr.], but rather he wishes subservient...

US Senate confirms Martin Makary to lead FDA

26 March

The United States Senate confirmed Dr. Martin Makary, a pancreatic surgeon, as commissioner of the Food and Drug Administration (FDA) in a 56-44 vote. The confirmation means that Makary, a surgeon at Johns Hopkins, will be in charge of regulation and oversight related to drugs, vaccines, food and other products. "Vaccines save lives, and I do believe that any child who dies of a vaccine-preventable illness is a tragedy in the modern era," Makary said...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.